WHO Issues Alert Over Acute Scarcity of Obesity Jabs

Under 10% of patients that would benefit from GLP-1 drugs such as Wegovy are able to get them, states the WHO as it issues its first advice on the medications.

Considering more than one billion individuals worldwide currently living with obesity, it is urging broader and more equitable access to GLP-1 medication.

Based on estimates, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.

"Our latest guidelines affirms that excess weight is a lifelong illness that can be managed with thorough and continuous treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and distribution challenges are key obstacles to universal access to the treatments that can assist patients in reducing significant weight, notes the organization.

Skinny Jab Scarcity

Despite the current best projected scenario, the manufacturing of such drugs might only reach approximately 100 million people – less than 10% of those who need them, as stated by the WHO.

The guideline urges countries and companies to expand access, by approaches such as voluntary licensing.

The intellectual property rights on the active ingredient – the primary component of the drug Wegovy – is due to expire in multiple nations in 2026.

The Way Weight-Loss Jabs Operate

These medications mimick a biological compound to reduce digestion speed, reduce hunger and enhance the sense of being full so users eat less.

Individuals usually begin shedding pounds after several weeks of starting on the regular doses.

Evidence indicates users may see weight return within a year of discontinuing the drug, when their typical appetite return.

Being carrying excess weight raises your likelihood for developing health problems, like type 2 diabetes, cardiovascular issues, stroke, and specific cancers.

Obesity affects people in every country and was associated with millions of deaths worldwide in 2024, as per the WHO.